Skip to main content
In Brief

Pfizer starts COVID-19 vaccine trial in young kids

A child receiving a vaccine.
(Image credit: Shutterstock)

Pfizer is testing its COVID-19 vaccine in children under age 12, according to news reports.

On Thursday (March 25), the company announced that it had begun a small trial of its vaccine in children 6 months to 11 years old, according to CNBC. Pfizer, which developed its shot in partnership with BioNTech, plans to enroll 144 kids in the Phase 1 trial, with the aim of finding the right dosage for kids of different ages.

The company hopes to have the results from this trial in the second half of 2021, and the vaccine could be authorized for kids under 12 by early 2022, according to The New York Times.

Pfizer's trial will test three different vaccine doses: 10, 20 and 30 micrograms per shot, according to the Times. (The Pfizer dose for adults is 30 micrograms per shot, according to CNBC.) The doses will first be tested in children ages 5 to 11, then 2 through 4 and finally 6 months to 2 years, the Times reported.

Once Pfizer determines the proper dose for each age group, the company will start a trial in 4,500 children; two-thirds will receive the real shot, and one-third will get a placebo. That trial will monitor children's immune response to the vaccine as well as look for side effects.

Earlier this month, Moderna announced it had started a trial of its COVID-19 vaccine in children ages 6 months to 11 years, Live Science previously reported. And Johnson & Johnson also plans to test its COVID-19 vaccine in kids and infants.

Both Pfizer and Moderna are already testing their shots in older children. (Pfizer has a trial in children ages 12 to 15 years, and Moderna has a trial in children ages 12 to 17.

Recently, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he projects that U.S. high school students could be vaccinated in the fall and elementary and middle school students in the first quarter of 2022, according to CNBC.

Originally published on Live Science.  

Rachael Rettner
Rachael has been with Live Science since 2010. She has a masters degree in journalism from New York University's Science, Health and Environmental Reporting Program. She also holds a Bachelor of Science in molecular biology and a Master of Science in biology from the University of California, San Diego.